HC Wainwright Has Bullish Forecast for ASMB FY2028 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Stock analysts at HC Wainwright upped their FY2028 earnings per share estimates for Assembly Biosciences in a report released on Wednesday, September 9th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of $0.84 per share for the year, up from their prior estimate of $0.80. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $2.28 per share. HC Wainwright also issued estimates for Assembly Biosciences’ FY2030 earnings at $3.32 EPS.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The business had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million.

Other research analysts have also recently issued research reports about the stock. UBS Group started coverage on shares of Assembly Biosciences in a report on Tuesday, September 1st. They set a “buy” rating and a $52.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Zacks Research raised Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Guggenheim reaffirmed a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Assembly Biosciences has an average rating of “Moderate Buy” and an average price target of $45.60.

Assembly Biosciences Stock Performance

ASMB stock opened at $32.87 on Thursday. The company’s 50 day moving average price is $29.68 and its 200 day moving average price is $28.36. The firm has a market capitalization of $669.23 million, a price-to-earnings ratio of 32.23 and a beta of 1.13. Assembly Biosciences has a fifty-two week low of $20.23 and a fifty-two week high of $39.71.

Institutional Trading of Assembly Biosciences

A number of hedge funds have recently added to or reduced their stakes in ASMB. RA Capital Management L.P. acquired a new position in shares of Assembly Biosciences in the third quarter valued at approximately $26,122,000. Janus Henderson Group PLC grew its position in Assembly Biosciences by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock valued at $23,479,000 after buying an additional 11,384 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new position in Assembly Biosciences in the 4th quarter valued at $22,625,000. Vanguard Group Inc. increased its stake in Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after buying an additional 248,287 shares during the period. Finally, Seven Fleet Capital Management LP increased its stake in Assembly Biosciences by 671.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock valued at $11,903,000 after buying an additional 377,000 shares during the period. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.